TXG is trading at $37.00 (3.6% up), extending a strong multi-day rally following a Barclays price target increase to $40 and a reaffirmed Overweight rating.
- The stock has climbed more than 11% over the past few sessions as investors respond positively to the upgraded outlook for 10x Genomics.
- Today’s price action is a continuation of analyst-driven momentum rather than fresh company-specific news.